target s/SARS-CoV

By Targets:	SARS-CoV (5)
By Research Areas:	Infection (5)

Targets Recommended: SARS-CoV Target Protein Ligand-Linker Conjugates Ligands for Target Protein for PROTAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99556

Tixagevimab AZD8895	SARS-CoV	Infection
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the *SARS-CoV-2* receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .

HY-P990052

Simaravibart

MAD-0004J08
SARS-CoV Infection

Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .

Simaravibart MAD-0004J08	SARS-CoV	Infection
Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the *SARS-CoV2* spike (S) glycoprotein receptor binding domain .

HY-145641

Crexavibart BMS-986413; C-144-LS	SARS-CoV	Infection
Crexavibart (BMS-986413; C-144-LS) is an IgG1_λ2 antibody that targets the *SARS-CoV2* spike (S) glycoprotein receptor-binding domain .

HY-P99467

Beludavimab BMS 4182137; VIR 7832	SARS-CoV	Infection
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of *SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC₅₀* value of 14.9 ng/mL and a K_d of 0.21 nM .

HY-P99104

Plutavimab

CoVI-AMG; STI-2020
SARS-CoV Infection

Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .

Plutavimab CoVI-AMG; STI-2020	SARS-CoV	Infection
Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .

Cat. No.	Product Name

HY-L027

Antiviral Compound Library	1270 compounds
Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs. MCE designs a unique collection of 1270 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.

Antiviral Compound Library

1270 compounds

Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs.

MCE designs a unique collection of 1270 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P99556

Tixagevimab AZD8895	SARS-CoV	Infection
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the *SARS-CoV-2* receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .

HY-P990052

Simaravibart

MAD-0004J08
SARS-CoV Infection

Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .

Simaravibart MAD-0004J08	SARS-CoV	Infection
Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the *SARS-CoV2* spike (S) glycoprotein receptor binding domain .

HY-145641

Crexavibart BMS-986413; C-144-LS	SARS-CoV	Infection
Crexavibart (BMS-986413; C-144-LS) is an IgG1_λ2 antibody that targets the *SARS-CoV2* spike (S) glycoprotein receptor-binding domain .

HY-P99467

Beludavimab BMS 4182137; VIR 7832	SARS-CoV	Infection
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of *SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC₅₀* value of 14.9 ng/mL and a K_d of 0.21 nM .

HY-P99104

Plutavimab

CoVI-AMG; STI-2020
SARS-CoV Infection

Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.